EUCTR2007-006934-33-BE
Active, not recruiting
Phase 1
A single center, open-label trial in subjects with severe renal impairment evaluating the dialysability of the sugammadex-rocuronium complex
V Organon0 sites15 target enrollmentJanuary 3, 2008
Conditionsot applicable
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- ot applicable
- Sponsor
- V Organon
- Enrollment
- 15
- Status
- Active, not recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •At least 18 years of age
- •ASA Class \= 4
- •Creatinine clearance (CLCR) \< 30 mL/min and clinical indication for dialysis
- •Hospitalization at ICU and scheduled for a (surgical) procedure under general anesthesia requiring neuromuscular relaxation with the use of rocuronium
- •Scheduled for a (surgical) procedure in supine position
- •Written informed consent (of the legal representative)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
Exclusion Criteria
- •Subjects known or suspected to have neuromuscular disorders impairing neuromuscular blockade and/or significant hepatic dysfunction
- •Subjects known or suspected to have a (family) history of malignant hyperthermia
- •Subjects known or suspected to have an allergy to narcotics, muscle relaxants or other medication used during general anesthesia
- •Subjects who have already participated in a sugammadex trial
- •Subjects who have participated in another clinical trial, not pre\-approved by NV Organon, within 30 days of entering into 19\.4\.333
- •Female subjects who are pregnant\*
- •Female subjects who are breast\-feeding
- •\* In female subjects pregnancy will be excluded both from medical history and by an hCG test within 24 hours before surgery except in females who are not of childbearing potential, i.e. at least 2 years menopausal or have undergone tubal ligation or an hysterectomy.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A single centre, open label trial investigating the absorption, metabolism and excretion of somapacitan after single subcutaneous dosing in healthy male subjectsgroeihormoondeficientiegrowth hormone deficiencyNL-OMON42854ovo Nordisk A/S7
Active, not recruiting
Phase 1
Investigation of acceptance, usability, safety and efficacy of the GlucoTab@MobileCare system for type 2 diabetes in domiciliary nursing careDiabetes mellitus type 2MedDRA version: 20.0 Level: PT Classification code 10067585 Term: Type 2 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2018-000863-98-ATMedical University of Graz10
Completed
Phase 4
A single-centre, open-label, non-controlled trial of acceptance, usability, safety and efficacy of a tablet based workflow and decision support system with incorporated basal-insulin algorithm for glycaemic management in patients with type 2 diabetes receiving domiciliary nursing careE11Type 2 diabetes mellitusDRKS00015059Medizinische Universität Graz, Universitätsklinik für Innere Medizin, Klinische Abteilung für Endokrinologie und Diabetologie9
Active, not recruiting
Not Applicable
An open single center study investigating the effects and side-effects of CRD007 in children with Duchenne Muscular Dystrophy (DMD -an inherited disorder which results in muscle degeneration) or Becker Muscular Dystrophy (BMD- an inherited disorder characterized by slowly progressive muscle weakness of the legs and pelvis) or children being symptomatic carriers for DMD or BMD.EUCTR2011-004667-76-SECardoz AB
Completed
Phase 1
A single dose study in healthy Japanese participants to evaluate the safety and pharmacokinetics of otilimab.Rheumatoid ArthritisJPRN-jRCT2071210132Yamada Masanori12